Noninvasive Antemortem Detection of Retinal Prions by a Fluorescent Tracer.
Patricia Aguilar-Calvo, Alejandro M Sevillano, Suhail Rasool, Kevin J Cao, Lyndsay M Randolph, Robert A Rissman, Stella T Sarraf, Jerry Yang, Christina J Sigurdson
Article in Journal of Alzheimer's disease : JAD, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 53% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 2 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
9 authors at 3 institutions in 1 country.
Patricia Aguilar-CalvoDepartment of Pathology, UC San Diego, La Jolla, CA, USA.
Alejandro M SevillanoDepartment of Pathology, UC San Diego, La Jolla, CA, USA.
Suhail RasoolAmydis, Inc., San Diego, CA.
Kevin J CaoDepartment of Chemistry and Biochemistry, University of California, San Diego, La Jolla, CA, USA.
Lyndsay M RandolphAmydis, Inc., San Diego, CA.
Robert A RissmanDepartment of Neurosciences, UC San Diego, La Jolla, CA, USA.
Stella T SarrafAmydis, Inc., San Diego, CA.
Jerry YangDepartment of Chemistry and Biochemistry, University of California, San Diego, La Jolla, CA, USA.
Christina J SigurdsonDepartment of Pathology, UC San Diego, La Jolla, CA, USA.
University of California, San Diego · USAmydis (United States) · USUniversity of California, Davis · US
Funding
USCADRC Diversity Supplement PachicanoP30AG066530 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI HELENA Chang CHUI · 2020 to 2026
$27.8M
Mechanisms of Prion Aggregation and Species BarriersR01NS069566 · NINDS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ESKO, JEFFREY D, RAVITS, JOHN · 2011 to 2025
$5.7M
Mechanisms of Prion SpreadR01NS076896 · NINDS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SIGURDSON, CHRISTINA · 2012 to 2021
$3.4M
Mechanisms of Prion Spread and Neuronal ToxicityR37NS076896 · NINDS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Christina Sigurdson · 2023 to 2026
$2.6M
Chemical design of amyloid targeting fluorescent probesRF1AG062362 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI THEODORAKIS, EMMANUEL A, YANG, JERRY · 2018 to 2020
$2.1M
Development of selective amyloid-responsive fluorescent probesRF1AG077802 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI YANG, JERRY · 2022 to 2022
$1.9M
Molecular basis of prion protein-induced neurodegenerationRF1NS121992 · NINDS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SIGURDSON, CHRISTINA · 2021 to 2023
$1.7M
Molecular basis of prion protein-induced neurodegenerationR01NS121992 · NINDS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SIGURDSON, CHRISTINA · 2024 to 2025
$963k
Probing prion clearance through interstitial fluid and perivascular pathwaysR21NS110409 · NINDS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SIGURDSON, CHRISTINA · 2018 to 2019
$433k
Development of Novel Prion Disease DiagnosticR43AG057421 · NIA · AMYDIS DIAGNOSTICS, INC. · PI SARRAF, STELLA · 2018 to 2018
$408k
Role of heparan sulfate in neural cell vulnerability to prionsK99AG061251 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI AGUILAR CALVO, PATRICIA · 2019 to 2021
backgroundNeurodegenerative diseases are widespread yet challenging to diagnose and stage antemortem. As an extension of the central nervous system, the eye harbors retina ganglion cells vulnerable to degeneration, and visual symptoms are often an early manifestation of neurodegenerative disease.
objectiveHere we test whether prion protein aggregates could be detected in the eyes of live mice using an amyloid-binding fluorescent probe and high-resolution retinal microscopy.
methodsWe performed retinal imaging on an experimental mouse model of prion-associated cerebral amyloid angiopathy in a longitudinal study. An amyloid-binding fluorophore was intravenously administered, and retinal imaging was performed at timepoints corresponding to early, mid-, and terminal prion disease. Retinal amyloid deposits were quantified and compared to the amyloid load in the brain.
resultsWe report that by early prion disease (50% timepoint), discrete fluorescent foci appeared adjacent to the optic disc. By later timepoints, the fluorescent foci surrounded the optic disc and tracked along retinal vasculature.
conclusionThe progression of perivascular amyloid can be directly monitored in the eye by live imaging, illustrating the utility of this technology for diagnosing and monitoring the progression of cerebral amyloid angiopathy.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Noninvasive Antemortem Detection of Retinal Prions by a Fluorescent Tracer. · full record | OpenQuestion